Home Daily Stock Opinions and Ratings Gilead Sciences Inc. (GILD-Q)

Trending stocks today

UBS Group AG Agco Corporation Bank of America CVS Health Corp Amazon.com, Inc. Accenture Ltd. UnitedHealth Group Inc Adobe Systems Netflix Inc. Canadian Natural Rsrcs Chubb Limited Enbridge Loblaw Companies Ltd Methanex Corp H&R Real Estate Inv Trust Bank of Montreal

Gilead Sciences Inc. (GILD-Q)

126 watching

NASDAQ:GILD

79.14
0.32 (0.40%) 1d
Mar 21, 2023, 8:00 pm
0
DON'T BUY

Gilead Sciences Inc.(GILD-Q)

22/02/2023
Gilead Sciences Inc.

No new drugs or trials. Doing nothing interesting. Prefers Eli Lilly.

biotechnology / pharmaceutical
Jim Cramer - Mad Money
$83.500
Unknown
UnlockRating
BUY

Gilead Sciences Inc.(GILD-Q)

28/10/2022
Gilead Sciences Inc.
It was upgraded today. What an earnings report, and they increased full-year guidance. Their HIV franchise continues to drive the top and bottom lines. Long-term, they continue to expand in oncolocy treatments--their pipeline looks fine.
biotechnology / pharmaceutical
Jim Lebenthal
$78.550
Owned
UnlockRating
BUY

Gilead Sciences Inc.(GILD-Q)

19/08/2022
Gilead Sciences Inc.
Likes healthcare. This pays a 4.5% dividend yield, because of the strength of their drugs. Likes their huge pipeline of drugs, spanning cell therapy, oncology and HIV. They just beat top and bottom lines and raised their 2022 guidance.
biotechnology / pharmaceutical
Rob Sechan, Managing Partner, New Edge Capital
$65.195
Owned
UnlockRating
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Gilead Sciences Inc.(GILD-Q)

08/02/2022
Gilead Sciences Inc.
(A Top Pick Oct 27/20, Up 6.6%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with GILD has triggered its stop at $64. To remain disciplined, we recommend covering the position at this time. We will look for better opportunities.
biotechnology / pharmaceutical
The Panic-Proof Portfolio (Stockchase Research)
$63.670
Unknown
UnlockRating
SELL

Gilead Sciences Inc.(GILD-Q)

03/02/2022
Gilead Sciences Inc.
He sold 2 years ago. "Patience required" is a polite way of saying "sell". He got tired of the same promises. Yes it's cheap, but not executing on R&D. Report on its 20B acquisition has been delayed.
biotechnology / pharmaceutical
Paul MacDonald
$65.780
No
UnlockRating
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Gilead Sciences Inc.(GILD-Q)

25/11/2021
Gilead Sciences Inc.
(A Top Pick Oct 27/20, Up 16.7%)Stockchase Research Editor: Michael O'Reilly Our PREVIOUS TOP PICK with GILD is progressing well. To remain disciplined, we recommend trailing up the stop (from $50) to $64 at this time.
biotechnology / pharmaceutical
The Panic-Proof Portfolio (Stockchase Research)
$70.070
Unknown
UnlockRating
WEAK BUY

Gilead Sciences Inc.(GILD-Q)

18/01/2021
Gilead Sciences Inc.
It is a healthcare name recently valued by investors. She likes to see a more visible pipeline in companies she buys. But this is a reasonable investment in this space.
biotechnology / pharmaceutical
Christine Poole
$63.330
No
UnlockRating
BUY

Gilead Sciences Inc.(GILD-Q)

07/12/2020
Gilead Sciences Inc.
They had good news about new drugs recently, but the stock still sold off. That's a sell signal.
biotechnology / pharmaceutical
Jim Cramer - Mad Money
$60.830
Unknown
UnlockRating
SELL ON STRENGTH

Gilead Sciences Inc.(GILD-Q)

13/11/2020
Gilead Sciences Inc.

It's bottoming because of interest rates. Sell it at $65. You can also swap this for Bristol-Myers.

biotechnology / pharmaceutical
Jim Cramer - Mad Money
$60.585
Unknown
UnlockRating
WATCH

Gilead Sciences Inc.(GILD-Q)

30/10/2020
Gilead Sciences Inc.
Likes the story. It has been frustrating since they like the story but the stock price has not reflected this. He thinks it is still undervalued. The core HIV franchise is stable and growing which gives good stability.
biotechnology / pharmaceutical
Shane Obata
$57.825
Owned
UnlockRating
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Gilead Sciences Inc.(GILD-Q)

27/10/2020
Gilead Sciences Inc.
Stockchase Research Editor: Michael O'Reilly As the first developer of COVID-19 treatment with its remdesivir (approved by the FDA). The product will be sold under the name of Veklury for patients that need hospitalization. This follows recent new treatments, one for breast cancer and another for HIV. Although the drugs are expensive, they have been proven to be effective in their treatment. We would buy this with a stop-loss at $50. Yield 4.53% (Analysts’ price target is $78.65)
biotechnology / pharmaceutical
The Panic-Proof Portfolio (Stockchase Research)
$60.020
Unknown
UnlockRating
DON'T BUY

Gilead Sciences Inc.(GILD-Q)

23/10/2020
Gilead Sciences Inc.
It has had a spotty history. It gained wide acknowledgement from their Hep C drug. The stock traded at an expanded multiple. The difficulty was that it was a solution and not a treatment, which means there is a terminal value. This is great for society but not for a business. They made acquisitions in the oncology department which hasn't done much since. It is an iteration for the company and not an embedded value.
biotechnology / pharmaceutical
Gordon Reid
$60.785
No
UnlockRating
DON'T BUY

Gilead Sciences Inc.(GILD-Q)

20/10/2020
Gilead Sciences Inc.
Very disappointing. They had their hepatitis C franchise that generated high cash flow, but they poorly invested this cash. They also lead in They have remdesivir, the first Covid treatment. So, he held onto Gilead over the summer, but remdesivir didn't turn out to be the big cure. Their M&A hasn't been productive, either. They recently made a very pricey acquisition which diversifies their business, but the price they paid was too highl they really need to execute. It's a value trap. He sold his shares six weeks ago.
biotechnology / pharmaceutical
Paul MacDonald
$60.395
No
UnlockRating
HOLD

Gilead Sciences Inc.(GILD-Q)

09/10/2020
Gilead Sciences Inc.
A big healthcare company. It has recently had a tough go, but they are still positive on it. Their HIV franchise continues to expand. The new management team has a good growth strategy that he views positively. Their oncology acquisitions were good moves. The assets were not cheap so execution needs to come through.
biotechnology / pharmaceutical
Shane Obata
$63.850
Owned
UnlockRating
premium

It's a Monthly Gems opinion which is available only for Premium members

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK

Gilead Sciences Inc.(GILD-Q)

11/05/2020
Gilead Sciences Inc.
In the race to find a treatment, Gilead currently leads with its remdesivir. It's the name on every investor's lips and trading screens. Tests so far indicate that remdesivir shortens the recovery time of some Covid-19 patients, specifically those who take remdesivir recover after 11 days, which is four days faster than those who did not take it. Last week, the American FDA allowed doctors to use this drug on an emergency basis on patients hospitalized with Covid-19. However, the FDA has not formally approved remdesivir, because it requires more testing. Currently, there are several ongoing clinical trials to test whether the drug can stop Covid-19 from replicating. In other words, remdesivir helps some patients heal faster, but isn't the magic bullet, at least not yet. In this horse race, Gilead is out front, but will it cross the finish line faster. Gilead pays a 3.4% based on a payout ratio of 65.9%, and trades at a PE just under 20x, with a forward PE of 13x.
biotechnology / pharmaceutical
The Monthly Gems by Allan Tong
$80.800
No
UnlockRating
Showing 1 to 15 of 253 entries
Next PageNext Page

Gilead Sciences Inc.(GILD-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 3

Stockchase rating for Gilead Sciences Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Gilead Sciences Inc.(GILD-Q) Frequently Asked Questions

What is Gilead Sciences Inc. stock symbol?

Gilead Sciences Inc. is a American stock, trading under the symbol GILD-Q on the NASDAQ (GILD). It is usually referred to as NASDAQ:GILD or GILD-Q

Is Gilead Sciences Inc. a buy or a sell?

In the last year, 3 stock analysts published opinions about GILD-Q. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Gilead Sciences Inc..

Is Gilead Sciences Inc. a good investment or a top pick?

Gilead Sciences Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Gilead Sciences Inc..

Why is Gilead Sciences Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Gilead Sciences Inc. worth watching?

3 stock analysts on Stockchase covered Gilead Sciences Inc. In the last year. It is a trending stock that is worth watching.

What is Gilead Sciences Inc. stock price?

On 2023-03-21, Gilead Sciences Inc. (GILD-Q) stock closed at a price of $79.14.

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Get Access To Watchlist

Latest Buy Signals

TD-TToronto Dominion (TD)
Toronto Dominion (TD)
$78.49
0.74 (0.93%)
RY-TRoyal Bank
Royal Bank
$129.78
1.23 (0.94%)
AQN-TAlgonquin Power & Utilities Corp
Algonquin Power & Utilities Corp
$10.78
0.13 (1.19%)
ADBE-QAdobe Systems
Adobe Systems
$374.22
11.34 (2.94%)
ARX-TArc Resources Ltd
Arc Resources Ltd
$15.67
0.30 (1.88%)
Advertising

Today's Top Picks

BMO-TBank of Montreal
Bank of Montreal
$118.83
1.67 (1.39%)
HR.UN-TH&R Real Estate Inv Trust
H&R Real Estate Inv Trust
$12.47
0.00 (0.00%)
MX-TMethanex Corp
Methanex Corp
$64.19
2.08 (3.14%)
L-TLoblaw Companies Ltd
Loblaw Companies Ltd
$114.22
-2.17 (-1.94%)
ENB-TEnbridge
Enbridge
$50.84
0.10 (0.20%)

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

LLY-NEli Lilly & Co.
Eli Lilly & Co.
$331.08
-2.52 (-0.77%)
CTC.A-TCanadian Tire Corporation Ltd. (A)
Canadian Tire Corporation Ltd. (A)
$166.05
1.31 (0.78%)
PD-TPrecision Drilling
Precision Drilling
$68.28
5.46 (7.40%)
AC-TAir Canada
Air Canada
$18.74
0.60 (3.10%)
VET-TVermilion Energy Inc
Vermilion Energy Inc
$17.57
0.54 (2.98%)

Most Recent Experts

Poole

Christine Poole

GlobeInvest Capital Management

Stockchase

Stockchase Discover

Stockchase

Panic-Proof (Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Berman

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Schwartz

Barry Schwartz

Baskin Wealth Management

Advertising
Advertising
logoTop pickslogoStockslogoRecentlogoWatchlist
© Stockchase Inc.